What is the IBD-BOOST Optimise study?
Many people with inflammatory Bowel Disease (including Crohn’s disease and ulcerative colitis) have troublesome symptoms of fatigue, pain and urgency to use the toilet. The OPTIMISE Study will test a checklist designed to find any medical issues which may be causing these symptoms and to ensure these are being treated as well as they can be (“Optimised”) by your NHS IBD care team.
Who can take part?
This study is open to people who:
- Have a diagnosis of Crohn’s disease, ulcerative colitis or another type of IBD.
- Are 18 or over
- Have completed the IBD-BOOST survey
- Live in England
- Are a patient at a participating NHS hospital
We are sending out postal and email invites to participate to people in Optimise who have completed the IBD-BOOST Survey and indicated that they have one or more IBD-related symptoms of fatigue, pain and/or urgency and would be interested in receiving support.
Which NHS Trusts are taking part?
The following hospitals are currently open to recruitment to this study:
- London North West University Hospital NHS Trust (St Mark’s Hospital)
More Hospitals will be open soon.
Who is organising and funding the research?
Professor Christine Norton is leading an experienced team of doctors, nurses and researchers. The trial is being funded by the National Institute of Health Research (NIHR) through their Programme Grants for Applied Research.
September 2018:Study received ethics approval
February 2019: Recruitment open.
June 2022: Recruitment to close
November 2023: Final report to be published
What organisations are involved?
King’s College London (KCL) and the Pragmatic Clinical trials Unit (PCTU) Queen Mary University of London are working in partnership with London North West University Healthcare NHS Trust (LNWUH). LNWUH is the sponsor for this trial based in the United Kingdom.
Who has reviewed this research?
IBD-BOOST Optimise has been reviewed and given favourable opinion by West Midlands -Black Country Research Ethics Committee (REC ID 19/WM/0107) and has approval from the Health Research Authority.